FN als StartseiteRealtimekurse aktiv
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
|---|---|---|---|---|
| 11:01 | Eli Lilly Stock Analysis: Buy, Hold, or Sell? | 8 | The Motley Fool | |
| 01:45 | Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy | 9 | Investor's Business Daily | |
| Di | DelveInsight Business Research, LLP: Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Biosciences | 381 | PR Newswire | |
| Di | (LLY) - Analyzing Eli Lilly and Co's Short Interest | 6 | Benzinga.com | |
| Di | Eli Lilly oral weight-loss candidate orfoglipron is potential winner; SA Summit | 6 | Seeking Alpha | |
| Di | Eli Lilly's oral weight-loss drug is potential winner, analyst says | 4 | Seeking Alpha | |
| Di | Lilly and Novo's brand values soar as GLP-1 drugs raise their profiles | 15 | FiercePharma | |
| Di | Here's How Much $1000 Invested In Eli Lilly and Co 10 Years Ago Would Be Worth Today | 3 | Benzinga.com | |
| Di | Opening Bell: Broadcom, Nvidia, Costco, Intuitive Surgical, Regeneron, Eli Lilly, Robinhood | 329 | Der Aktionär TV | |
| Mo | Spotlight on Eli Lilly and Co: Analyzing the Surge in Options Activity | 16 | Benzinga.com | |
| Mo | How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi | 14 | CNBC | |
| Mo | Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. | 19 | The Motley Fool | |
| Sa | Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy? | 26 | The Motley Fool | |
| Sa | Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster | 19 | The Motley Fool | |
| Fr | Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised) | 8 | Zacks | |
| Fr | Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails | 5 | Zacks | |
| Fr | ELI LILLY: Wichtige Zulassung in Sicht? | 567 | Bernecker Börsenbriefe | |
| Do | Eli Lilly's GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH | 23 | PMLiVE | |
| 12.06. | Eli Lilly and Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings) | 19 | Benzinga.com | |
| 12.06. | Lilly's Retevmo gains traditional approval in thyroid cancer | 5 | Seeking Alpha |
Seite:
1 2 3 4 5 Weiter >>
1.177 Nachrichten in den letzten 12 Monaten
ELI LILLY AND COMPANY gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 831,50 Euro und damit +0,17 % im Plus. Die Dividendendrendite beträgt aktuell +0,54 % (berechnet anhand der Ausschüttung von 4,50 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
